Key facts
- FYR Diagnostics’s last known valuation is $19.0M (Sep 2025).
- It has raised $8.7M across 1 recorded rounds; the latest was Early Stage VC ($8.0M) in Aug 2024.
- Notable investors include National Institutes of Health, MonTEC (Accelerator), National Institutes of Neurological Disorders and Stroke, The Sontag Foundation, Two Bear Capital — 6 tracked in total.
- FYR Diagnostics has filed 1 Form D with the SEC, most recently Aug 2024 ($8.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for FYR Diagnostics
Funding rounds
1 roundsAbout FYR Diagnostics
Developer of a biomarker detection technology designed to tackle burdensome diseases in human healthcare and agriculture with large unmet clinical needs. The company's technology commercializes and implements novel technologies to accelerate the prediction, diagnosis and management of human and agricultural diseases, enabling healthcare industries to address disorders in humans that have widely ineffective treatments and diagnostics.
- Sector
- Healthcare
- HQ
- Missoula, MT, United States
- Founded
- 2016
- Employees
- 19
- Website
- fyr.bio/
- Ownership
- Privately Held (backing)
FYR Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FYR Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FYR Diagnostics in its N-PORT filings yet. We sweep new filings monthly.